Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-04-09
2011-11-29
Peng, Bo (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S194100, C424S196110, C424S201100, C424S227100, C424S192100, C530S350000, C530S402000, C977S795000, C977S797000, C977S798000, C977S800000, C977S801000, C977S802000
Reexamination Certificate
active
08067011
ABSTRACT:
The present invention provides a targeted multi-layered drug delivery system for the delivery of cytotoxic agents to B-cells.
REFERENCES:
patent: 5133961 (1992-07-01), Ellis et al.
patent: 5420026 (1995-05-01), Payne
patent: 5439686 (1995-08-01), Desai et al.
patent: 5498421 (1996-03-01), Grinstaff et al.
patent: 5670630 (1997-09-01), Thill
patent: 5714316 (1998-02-01), Weiner et al.
patent: 5858726 (1999-01-01), Payne
patent: 5863541 (1999-01-01), Samulski et al.
patent: 5980901 (1999-11-01), Shih et al.
patent: 6046173 (2000-04-01), Forstova et al.
patent: 6063370 (2000-05-01), Dadey
patent: 6096331 (2000-08-01), Desai et al.
patent: 6204059 (2001-03-01), Samulski et al.
patent: 6231864 (2001-05-01), Birkett
patent: 6387662 (2002-05-01), Liang et al.
patent: 6420160 (2002-07-01), Bloch
patent: 6506405 (2003-01-01), Desai et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6537579 (2003-03-01), Desai et al.
patent: 6573009 (2003-06-01), Noda et al.
patent: 6602706 (2003-08-01), Fallaux et al.
patent: 6602932 (2003-08-01), Feldheim et al.
patent: 6616944 (2003-09-01), Kissel et al.
patent: 6620617 (2003-09-01), Mathiowitz et al.
patent: 6627202 (2003-09-01), Murray et al.
patent: 6696038 (2004-02-01), Mahato et al.
patent: 6710173 (2004-03-01), Binley et al.
patent: 6749868 (2004-06-01), Desai et al.
patent: 6753006 (2004-06-01), Desai et al.
patent: 6984386 (2006-01-01), Douglas et al.
patent: 7056704 (2006-06-01), Tuschl et al.
patent: 7078194 (2006-07-01), Withers et al.
patent: 7101995 (2006-09-01), Lewis et al.
patent: 7282199 (2007-10-01), Gao et al.
patent: 7332321 (2008-02-01), Belcher et al.
patent: 7332337 (2008-02-01), van Es et al.
patent: 7344872 (2008-03-01), Gao et al.
patent: 7422902 (2008-09-01), Wheeler et al.
patent: 2004/0005338 (2004-01-01), Bachmann et al.
patent: 2004/0247660 (2004-12-01), Singh
patent: 2005/0004002 (2005-01-01), Desai et al.
patent: 2005/0089526 (2005-04-01), Moore et al.
patent: 2006/0292118 (2006-12-01), Kuroda et al.
patent: 2006/0292174 (2006-12-01), de los Rios et al.
patent: 2007/0248573 (2007-10-01), Sturino
patent: 2007/0249554 (2007-10-01), Tuszynski
patent: 2007/0258889 (2007-11-01), Douglas et al.
patent: 2007/0269370 (2007-11-01), Davis et al.
patent: 2007/0280962 (2007-12-01), Murray
patent: 2008/0050343 (2008-02-01), Wilson et al.
patent: 2008/0050345 (2008-02-01), Wilson et al.
patent: 2008/0069802 (2008-03-01), Davis et al.
patent: 2008/0075737 (2008-03-01), Gao et al.
patent: 2008/0075740 (2008-03-01), Gao et al.
patent: 2008/0090281 (2008-04-01), Wilson et al.
patent: 2008/0125385 (2008-05-01), Hajjar et al.
patent: 2008/0131928 (2008-06-01), Handa et al.
patent: 2009/0226525 (2009-09-01), de los Rios et al.
patent: 863987 (1998-09-01), None
patent: 920514 (1999-06-01), None
patent: 1204761 (2002-05-01), None
patent: 1219705 (2002-07-01), None
patent: 1 447 079 (2004-08-01), None
patent: 1563834 (2005-08-01), None
patent: 1845163 (2007-10-01), None
patent: 1849799 (2007-10-01), None
patent: 1944043 (2008-07-01), None
patent: WO 95/32706 (1995-12-01), None
patent: WO-99/40214 (1999-08-01), None
patent: WO 00/09158 (2000-02-01), None
patent: WO-01/02551 (2001-01-01), None
patent: WO 01/12235 (2001-02-01), None
patent: WO 02/44204 (2002-06-01), None
patent: WO-2004/047812 (2004-06-01), None
patent: WO-2006/033679 (2006-03-01), None
patent: WO-2006/066048 (2006-06-01), None
patent: WO-2007/126764 (2007-11-01), None
patent: WO-2007/136263 (2007-11-01), None
patent: WO-2008/008881 (2008-01-01), None
patent: WO-2008/010864 (2008-01-01), None
patent: WO-2008/021908 (2008-02-01), None
patent: WO-2008/024427 (2008-02-01), None
patent: WO-2008/027084 (2008-03-01), None
patent: WO-2008/037504 (2008-04-01), None
patent: WO-2008/048288 (2008-04-01), None
patent: WO-2008/051101 (2008-05-01), None
patent: WO-2008/054826 (2008-05-01), None
patent: WO-2008/124165 (2008-10-01), None
Larsen SR, Rasko JE. “Lymphoproliferative disorders: prospects for gene therapy.” Pathology. Dec. 2005;37(6):523-33.
de Kruif J, Storm G, van Bloois L, Logtenberg T. “Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes.” FEBS Lett. Dec. 16, 1996;399(3):232-6.
Mansfield E, Amlot P, Pastan I, FitzGerald DJ. “Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.” Blood. Sep. 1, 1997;90(5):2020-6.
Moreira J. et al. “Use of the post-insertion technique to insert peptide ligands into pre-formed Stealth liposomes with retention of binding activity and cytotoxicity” Pharmaceutical Research 19(3):265-269, 2002.
Scott MD, et al. “Chemical camouflage of antigenic determinants: stealth erythrocytes” Proc Natl Acad Sci U S A. Jul. 8, 1997;94(14):7566-71.
Xia H, et al. “siRNA-mediated gene silencing in vitro and in vivo”. Nat Biotechnol 2002; 20: 1006-10.
Rubinson DA, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33:401-6.
Fasbender et al., “Complexes of Adenovirus with Polycationic Polymers and Cationic Lipids Increase the Efficiency of Gene Transfer in Vitro and Vivo”,J. Biol. Chem., 272(10): 6479-6489 (1997).
Boisgerault et al. “Virus-like particles: a new family of delivery systems” Expert Rev. Vaccines 1(1):101-9, 2002.
Bottcher et al. “Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy” Nature 386:88-91, 1997.
Brumfield et al. “Heterologous expression of the modified coat protein of Cowpea chlorotic mottle bromovirus results in the assembly of protein cages with altered architecture and function” J. gen Virol 85:1049-1053, 2004.
Crommelin et al. “Nanotechnological approaches for the delivery of macromolecules” J Controlled Release 87:81-88, 2003.
Crowther et al. “Three-dimensional structure of hepatitis B virus core particles determined by electronic cryomicroscopy” Cell 77:943-50, 1994.
DeNardo et al. “Efficacy and Toxicity of 67Cu-2IT-BAT-Lym-1 Radio-immunoconjugate in Mice Implanted with Human Burkitt's Lymphoma (Raji)” Cln. Cancer Res., 3:71-79 (1997).
Fernandez et al. “Activated protein C Correlates Inversely with Thrombin Levels in Resting Healthy Individuals” Am. J. Hematol., 56:29-31 (1997).
Haag “Supramolecular drug-delivery systems based on polymeric core-shell architectures” Angew Chem Int Ed 43:278-282, 2004.
International Search Report for PCT/US07/08938, dated Oct. 7, 2008.
International Search Report for PCT/US08/04585, dated Mar. 17, 2009.
International Search Report for PCT/US05/18456, dated Sep. 13, 2006.
Jenny et al. “A critical review of the methods for cleavage of fusion proteins with thrombin and factor Xa” Prot Express Purif 31:1-11, 2003.
Kayser et al. “Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs” Parasitol Res 90:S63-S270, 2003.
Lamprecht et al. “Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease” J Pharmacol Exp Ther 299:775-81, 2002.
Liu et al. “Nanostructured materials designed for cell binding transduction” Biomacromolecules 2:362-368, 2001.
Lundstrom et al. “Breakthrough in cancer therapy: encapsulation of drugs and viruses” Curr Drug Disc: Nov. 2002, pp. 19-23.
Maeda “The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting” Adv Enzyme Regul 41:189-207, 2001.
Managit et al. “Targeted and sustained drug delivery using PEGylated galatosylated liposomes” Int J Pharmaceutics 266:77-84, 2003.
Martin et al. “Immunospecific targeting of lipsomes to cells: a novel and efficient method for covalent attachment of Fab′ fragments via disulfide bonds” Biochemistr
Bullock Timothy L.
Davis Claude Geoffrey
de los Rios Miguel A.
Johnson Patrick T.
Oh Kenneth J.
Chimeros, Inc.
Goodwin & Procter LLP
Peng Bo
LandOfFree
Compositions and methods for treating B-cell malignancies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating B-cell malignancies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating B-cell malignancies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4284122